Instrument Inactif

Communiqués Abliva AB

Actions

ABLI

SE0002575340

Recherche biotechnologique et médicale

Communiqués

17/03/25	BioStock: Last trading day for Abliva - the company leaves Nasdaq Stockholm	AQ
03/03/25	Delisting of the shares of Abliva: last day of trading 17 March 2025	AQ
26/02/25	Notice of Extraordinary General Meeting in Abliva AB (publ)	AQ
25/02/25	Abliva applies for delisting and will convene an extraordinary general meeting	AQ
21/02/25	Abliva AB Year-End Report January – December 2024	AQ
21/02/25	Abliva : Year End Report January December 2024	PU
10/02/25	BioStock: Pharming completes bid for Abliva	AQ
15/12/24	Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming	AQ
09/12/24	Abliva Announces Publication of Results from Phase 1a/b Study of KL1333 in the Scientific Journal Brain	AQ
04/12/24	BioStock: From mutation to solution - Abliva gains ground	AQ
29/11/24	Abliva : Interim Report January - September 2024	PU
29/11/24	Abliva AB Interim Report January – September 2024	AQ
04/11/24	Abliva will present at the BioStock Life Science Summit, November 21	AQ
18/09/24	BioStock: Abliva leads the fight against mitochondrial disease	AQ
16/09/24	Abliva : Join Abliva for World Mitochondrial Disease Week 2024, September 16 - 22	PU
16/09/24	Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22	AQ
30/08/24	Amended number of shares and votes in Abliva AB (publ)	AQ
22/08/24	Abliva : Interim Report January - June 2024	PU
22/08/24	Abliva AB Interim Report January – June 2024	AQ
24/07/24	Abliva's CEO to BioStock: "One step closer to a marketed medicine"	AQ
19/07/24	Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion	AQ
18/07/24	Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease	AQ
31/05/24	Amended number of shares and votes in Abliva AB (publ)	AQ
30/05/24	Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease	AQ
29/05/24	Ablivas CEO to BioStock: "We remain on track for the interim analysis early in Q3"	AQ